Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SLC16A3 | O15427 | 6/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185403 | 0.98 | AKR1C3 (0.46) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL7178647 | 0.95 | AKR1C3 (0.48) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL7188497 | 0.88 | AKR1C3 (0.52) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL7470589 | 0.84 | FOLH1 (0.59) | FOLH1ALDH1A1SLC16A3TSHR | |
| SCHEMBL28423359 | 0.84 | AKR1C3 (0.59) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL945386 | 0.83 | AKR1C3 (0.47) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL17318743 | 0.83 | AKR1C3 (0.47) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL3642864 | 0.83 | BID (0.49) | AKR1C3 | |
| SCHEMBL28882596 | 0.83 | AKR1C3 (0.47) | AKR1C3CYP19A1GAAMAPTL3MBTL1 | |
| SCHEMBL1062035 | 0.83 | AKR1C3 (0.50) | AKR1C3CYP19A1GAAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | claimed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | claimed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | claimed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | claimed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0966456-B1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-0966456-A4 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | RES FOUNDATION OF (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0966456-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5811452-A | ADMINISTERING WITH PACLITAXEL OR DOXORUBICIN | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-09-22 | — | — | US | disclosed |
| WO-1998030553-A1 | TAXOID REVERSAL AGENTS FOR DRUG-RESISTANCE IN CANCER CHEMOTHERAPY AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-07-16 | — | — | WO | disclosed |